ArticleJournal of translational medicine2010
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.
Article in Journal of translational medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring.Cancers · 2025Review
- The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.Seminars in cancer biology · 2018Review
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.Journal of hematology & oncology · 2016Review
- The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Preamble to the 2015 SITC immunotherapy biomarkers taskforce.Journal for immunotherapy of cancer · 2015Article
- Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries.Molecular and clinical oncology · 2014Article
- Immune response to sipuleucel-T in prostate cancer.Cancers · 2012Article
- Multiplex serum biomarker assessments: technical and biostatistical issues.Journal of translational medicine · 2011Article
- SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.Journal of translational medicine · 2011Article
- Biomarkers in T cell therapy clinical trials.Journal of translational medicine · 2011Review
- Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.Journal of translational medicine · 2011Article
- The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program.Journal of translational medicine · 2011Review
- Translational Medicine is developing in China: a new venue for collaboration.Journal of translational medicine · 2011Article
- Immunotherapy of cancer in 2012.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The International Society for Biological Therapy of Cancer (iSBTc, recently renamed the Society for Immunotherapy of Cancer, SITC) hosted a one-day symposium at the National Institutes of Health on September 30, 2010 to address development and application of biomarkers in cancer immunotherapy. The symposium, titled Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Task Force, gathered approximately 230 investigators equally from academia, industry and governmental/regulatory agencies from around the globe for panel discussions and presentations on the following topics: 1) immunologic monitoring: standardization and validation of assays; 2) correlation of immunity to biologic activity, clinical response and potency assays; 3) novel methodologies for assessing the immune landscape: clinical utility of novel technologies; and 4) recommendations on incorporation of biomarkers into the clinical arena. The presentations are summarized in this report; additional program information and slides are available online at the iSBTc/SITC website.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.